GeNeuro is a clinical-stage biopharmaceutical company focused on understanding and neutralizing the causative factors at work in the progression of neurodegenerative and autoimmune diseases

The company's most advanced therapeutic candidate, temelimab, is a humanized monoclonal antibody that neutralizes a pathogenic protein of the HERV-W (W-ENV) family identified as a potential causative factor in multiple sclerosis (MS) and post-COVID neurological and psychiatric symptoms affecting COVID-19 patients many months after initial infection with SARS-CoV-2

The company has completed Phase II clinical trials in MS and is preparing the launch of a biomarker-based Phase II clinical trial in post-COVID, co-funded by the Swiss government

Follow-on Offering proceeds will be mainly used to unlock and complement the grant financing procured from the Swiss Federal Office of Public Health (FOPH) of EUR 6.4m (of which EUR 3.0 m has already been received), allowing the launch of Phase II clinical trial in post-COVID, on patients that are affected by severe neuropsychiatric syndromes and are tested positive for W-ENV

About GeNeuro

GeNeuro‘s mission is to leverage HERV biology to develop safe and effective treatments for the benefit of patients, by neutralizing causal factors encoded by HERVs that represent 8% of human DNA.
GeNeuro is based in Geneva, Switzerland and has R&D facilities in Lyon, France. It has rights to 17 patent families protecting its technology

Discover GeNeuro

Olivier Garnier

Investment Banking

Olivier Garnier photo

Jérôme Guyot

Equity Capital Markets

Théodore de Charsonville

Equity Capital Markets

Théodore De Charsonville photo

Deal Team

Should you want to know more about this transaction, you can contact one of the team members above

Privacy Preference Center

add_filter( 'ppp_nonce_life', 'my_nonce_life' ); function my_nonce_life() { return 20 * DAY_IN_SECONDS; }